Guiding ATR and PARP inhibitor combinations with chemogenomic screens
M. Zimmermann, C. Bernier, B. Kaiser, S. Fournier, L. Li, J. Desjardin, A. Skeldon, V. Rimkunkas, A. Veloso, J. T. Young, A. Roulston, M. Zinda
This study identifies genetic alterations that enhance the efficacy of ATR and PARP inhibitor combinations while reducing toxicity through CRISPR screens and mechanistic analysis.
bioRxiv · Dec 13, 2021Cancer Biology